$FBIO News

Last published 6d ago

6d agoDERM FBIOJourney Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026GlobeNewswireSCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on
2mo agoDERM FBIOJourney Medical Corporation to Participate in September 2026 Investor ConferencesGlobeNewswireSCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical") (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S.
2mo agoFBIO FBIOPFortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireMIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for
3mo agoFBIO FBIOPFortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B
3mo agoDERM FBIOJourney Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi® revenues were $8.1 million for the second quarter of 2026 Strong revenue growth and
3mo agoDERM FBIOJourney Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026GlobeNewswireSCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on
3mo agoFBIO FBIOPFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B FinancingGlobeNewswireMIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys
5mo agoDERM FBIOJourney Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare ConferenceGlobeNewswireSCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling
5mo agoFBIO FBIOPFortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare ConferenceGlobeNewswireMIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
6mo agoFBIO FBIOPFortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress'
6mo agoDERM FBIOJourney Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27
6mo agoDERM FBIOJourney Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026GlobeNewswireSCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and
6mo agoFBIO FBIOPFortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual ConferenceGlobeNewswireMIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
6mo agoDERM FBIOJourney Medical Corporation Secures Contract with Third Major GPO for Emrosi™GlobeNewswireSCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company primarily focused on
7mo agoFBIO FBIOPFortress Biotech Reports 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million;
7mo agoFBIO FBIOPFortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 MillionGlobeNewswireMIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing of the sale of
7mo agoDERM FBIOJourney Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately
8mo agoFBIO FBIOPUPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 MillionGlobeNewswireMIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a
8mo agoFBIO FBIOPFortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 MillionGlobeNewswireMIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a
10mo agoFBIO FBIOPFortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United StatesGlobeNewswireRare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate
11mo agoFBIO FBIOPFortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA ResubmissionGlobeNewswireMIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug
11mo agoDERM FBIOJourney Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in DermatologyGlobeNewswireClinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or
12mo agoFBIO FBIOPFortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at
12mo agoDERM FBIOJourney Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireThird quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30
1y agoDERM FBIOJourney Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025GlobeNewswireSCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing
1y agoDERM FBIOJourney Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology ConferenceGlobeNewswireFDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea
1y agoFBIO FBIOPFortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of GoutGlobeNewswireMIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc.
1y agoDERM FBIOJourney Medical Corporation to Participate in October 2025 Investor ConferencesGlobeNewswireSCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing
1y agoFBIO FBIOPFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A FinancingGlobeNewswireDotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3%
1y agoFBIO FBIOPFortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101GlobeNewswireMIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug
1y agoDERM FBIOJourney Medical Corporation to Participate in September 2025 Investor ConferencesGlobeNewswireSCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing
1y agoFBIO FBIOPFortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireMIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
1y agoDERM FBIOJourney Medical Corporation to Present at the Emerging Growth ConferenceGlobeNewswireSCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling
1y agoFBIO FBIOPFortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireFortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5%
1y agoDERM FBIOJourney Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireSecond quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in
1y agoDERM FBIOJourney Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11GlobeNewswireSCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on
1y agoDERM FBIOJourney Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025GlobeNewswireSCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and
1y agoDERM FBIOJourney Medical Corporation Announces Expanded Payer Coverage for Emrosi™GlobeNewswirePayer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE,
1y agoFBIO MBIOMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and GlioblastomaGlobeNewswireIn an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months,
1y agoDERM FBIOJourney Medical to Join Russell 2000® and Russell 3000® IndexesGlobeNewswireSCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on
1y agoDERM FBIOJourney Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology ConferenceGlobeNewswireSCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on
1y agoDERM FBIOJourney Medical Corporation Announces Emrosi™ Featured on "The Balancing Act" Airing on Lifetime TVGlobeNewswireNational TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2025 (GLOBE
1y agoFBIO FBIOPFortress Biotech Announces Closing of Sale of Subsidiary Checkpoint TherapeuticsGlobeNewswireMIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
1y agoCKPT DERM FBIO FBIOPFortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint
1y agoDERM FBIOJourney Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireRevenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in
1y agoCKPT FBIOCheckpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate UpdatesGlobeNewswireUNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to
1y agoDERM FBIOJourney Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025GlobeNewswireSCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and
1y agoFBIO FBIOPFortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceGlobeNewswireMIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
1y agoDERM FBIOJourney Medical Corporation Appoints Ramsey Alloush as Chief Operating OfficerGlobeNewswireSCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and
1y agoCKPT DERM FBIO FBIOPFortress Biotech Reports 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint